COMMUNIQUÉS West-GlobeNewswire
-
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique
14/04/2026 -
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
14/04/2026 -
Transactions in connection with share buy-back program
14/04/2026 -
PannTheraPi Announces Significant Clinical Development and Strategic Milestones
14/04/2026 -
Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026
14/04/2026 -
Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma
14/04/2026 -
Rapid Nutrition Strengthens Capital Markets Infrastructure with Appointment of Bowsprit Partners
14/04/2026 -
Vital Step GLP-1 Claims Evaluated: Trusted Doctor-Prescribed GLP-1 Weight Loss Medication with No Hidden Fees
14/04/2026 -
Elite Force XL Male Enhancement Gummies Claims Evaluated: Effective Men's Formula for Steel Power Support
14/04/2026 -
GloraMD Face Lift Serum Claims Evaluated: Liquid Anti-Aging Wrinkle Serum Solution for Skin Renewal
14/04/2026 -
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
13/04/2026 -
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
13/04/2026 -
Clean Eye Claims Evaluated: The CleanEye Vision Care Capsules for Retina Clear Visual Support
14/04/2026 -
Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451
13/04/2026 -
Les données intermédiaires de l'essai pivot testant cema-cel mettent en évidence la solidité de la plateforme CAR-T allogénique de Cellectis
13/04/2026 -
Biomerica Reports Third Quarter Fiscal 2026 Financial Results
14/04/2026 -
AIM ImmunoTech Provides Routine Update on Annual Filings
14/04/2026 -
Celldex to Present at Upcoming Investor Conference
13/04/2026 -
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
13/04/2026
Pages